Carrie Brockway is the Executive Director of SeaBridge with the Allen Institute, drawn to the intersection of compelling science and enabling technology—and to the collaborative mission of the Seattle Hub for Synthetic Biology. She is motivated by the therapeutic potential of programming cells, and by building communities and capabilities that help translate discovery into impact. Brockway earned a B.S. in Chemistry from Miami University (Ohio) and a Ph.D. in Chemistry from the University of Utah. She began her career at Pfizer in 2000 as a Senior Principal Scientist and went on to hold roles spanning science, business development, and senior operations—including work in Pfizer’s neuroscience development unit and senior-level operations for the Chief Medical Officer, partnering closely with internal leadership and external organizations. After more than a decade in Big Pharma, she completed an MBA at MIT Sloan to deepen her strategic and analytical toolkit. She then joined the Broad Institute as a Senior Advisor, serving on the leadership team and working closely with Aviv Regev, an experience she describes as an immersion in innovative, highly collaborative research. Brockway later helped launch startup ventures, including Ascidian, where she spent over five years and served as Senior Vice President and Head of Operations. At SeaBridge, she leads a five-year effort—supported by the Washington Research Foundation, Chan Zuckerberg Initiative, and UW’s Brotman Baty Institute—anchored by a postdoctoral fellowship program and LaunchPad, which advances new therapeutics, diagnostics, and cell-based technologies from Seattle Hub research.